Aadi Bioscience, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$39.6M
Doctors Paid
583
Transactions
2,682
2024 Total
$21.2M
Payment Breakdown by Category
Research$38.8M (97.9%)
Consulting$342,321 (0.9%)
Food & Beverage$51,210 (0.1%)
Travel$29,303 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $38.8M | 1,512 | 97.9% |
| Honoraria | $366,675 | 141 | 0.9% |
| Consulting Fee | $342,321 | 82 | 0.9% |
| Food and Beverage | $51,210 | 827 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $42,305 | 19 | 0.1% |
| Travel and Lodging | $29,303 | 66 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $14,000 | 4 | 0.0% |
| Education | $5,024 | 31 | 0.0% |
Payments by Type
Research
$38.8M
1,508 transactions
General
$850,838
1,170 transactions
Ownership
$0
4 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/_TSC2 Genes (PRECISION 1) | $14.9M | 0 | 51 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1TSC2 Genes PRECISION 1 | $7.1M | 0 | 31 |
| Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | $6.3M | 0 | 327 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes | $3.7M | 2 | 467 |
| A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes. | $2.7M | 1 | 271 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors NETs of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $2.5M | 0 | 4 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract Lung or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $494,611 | 0 | 315 |
| Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | $475,934 | 0 | 23 |
| A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions | $294,203 | 0 | 2 |
| Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas | $218,068 | 0 | 8 |
| A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa | $58,869 | 0 | 5 |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | $38,440 | 0 | 4 |
Payments by Medical Specialty
Top Paid Doctors — Page 17
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Deanna Bianchini, Pa-C, PA-C | Medical | Exton, PA | $24.58 | $0 |
| Mrs. Lisa Ulmer, Pa-C, PA-C | Medical | Philadelphia, PA | $24.58 | $0 |
| Dr. Wesleigh Edwards, Md, Phd, MD, PHD | Hospitalist | San Diego, CA | $24.18 | $0 |
| Olivia Hightower, Md, MD | Medical Oncology | Gulfport, MS | $24.15 | $0 |
| Dr. Sunny Philip, M.d, M.D | Hematology & Oncology | Lodi, CA | $24.12 | $0 |
| Tiffany Brown, Dnp, DNP | Adult Health | Stanford, CA | $24.06 | $0 |
| Cynthia Cruz-Kuang, Np, NP | Family | South Pasadena, CA | $24.03 | $0 |
| Ms. Kavitha Narayanan, Np-C, NP-C | Nurse Practitioner | Los Angeles, CA | $24.03 | $0 |
| Rebecca Umayam, F.n.p, F.N.P | Family | Los Angeles, CA | $24.03 | $0 |
| Dr. Lydia Chow, M.d, M.D | Hematology & Oncology | West Covina, CA | $23.93 | $0 |
| Dr. Jorge Chaves, M.d, M.D | Hematology & Oncology | Tacoma, WA | $23.91 | $0 |
| Rebecca Waxman | Physician Assistant | Tonasket, WA | $23.91 | $0 |
| Hong Cai, Pa, PA | Physician Assistant | Tacoma, WA | $23.91 | $0 |
| Dr. Thomas Forlenza, Md, MD | Hematology & Oncology | Staten Island, NY | $23.60 | $0 |
| Manas Agastya, M.d, M.D | Internal Medicine | Las Vegas, NV | $23.26 | $0 |
| Silvia Dominguez, Np, NP | Nurse Practitioner | Visalia, CA | $23.01 | $0 |
| Tracy Dobbs, Md, MD | Hematology & Oncology | Knoxville, TN | $22.73 | $0 |
| Sherri Carlisle, Fnp, FNP | Family | Morristown, TN | $22.73 | $0 |
| Jenny Le | Prosthodontics | Westminster, CA | $22.56 | $0 |
| Alan Grosset, Md, MD | Hematology & Oncology | Ft Lauderdale, FL | $22.56 | $0 |
| Francisca Estrada, Aprn, APRN | Family | Aventura, FL | $22.36 | $0 |
| Dr. Edgardo Santos, Md, MD | Hematology & Oncology | Fort Lauderdale, FL | $22.35 | $0 |
| Kelly Conley, Np, NP | Women's Health | Grand Rapids, MI | $22.13 | $0 |
| Dr. Christopher Hummel, D.o, D.O | Gynecologic Oncology | Grand Rapids, MI | $22.13 | $0 |
| Dr. Mae Zakhour | Gynecologic Oncology | Grand Rapids, MI | $22.13 | $0 |
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc. has made $39.6M in payments to 583 healthcare providers, recorded across 2,682 transactions in the CMS Open Payments database. In 2024, the company paid $21.2M. The top product by payment volume is FYARRO ($23.1M).
Payments were distributed across 46 medical specialties. The top specialty by payment amount is Medical Oncology ($341,757 to 68 doctors).
Payment categories include: Food & Beverage ($51,210), Consulting ($342,321), Research ($38.8M), Travel & Lodging ($29,303).
Aadi Bioscience, Inc. is associated with 3 products in the CMS Open Payments database.